Efficacy and safety of endometrial ablation for treating abnormal uterine bleeding in pre- and postmenopausal women with liver cirrhosis

• Published in: The journal of obstetrics and gynaecology research 2016-12, Vol.42 (12), p.1753-1760
• Main Authors: Liu, Qing, Li, Xiu-lan, Liu, Ji-Juan, Song, Xiao-Hong, Jiang, Xiao-Ying, Li, Wei, Zhang, Hua, Pan, Calvin Q.
• Format: Article
• Language: English
• Subjects: abnormal uterine bleeding; Adult; Amenorrhea; Bleeding; Cirrhosis; endometrial ablation; Endometrial Ablation Techniques - adverse effects; Endometrial Ablation Techniques - methods; Endometrium; Female; Hemorrhage; hepatic cirrhosis; Humans; Hysterectomy; Liver; Liver cirrhosis; Liver Cirrhosis - complications; Longevity; Middle Aged; NovaSure; Patient Satisfaction; Post-menopause; Postmenopause; Premenopause; Prospective Studies; Quality of Life; Treatment Outcome; Uterine Hemorrhage - complications; Uterine Hemorrhage - surgery; Uterus
• ISSN: 1341-8076; 1447-0756
• DOI: 10.1111/jog.13124

Aim Abnormal uterine bleeding (AUB) occurs in 10–30% of women of reproductive age and up to 61% of cirrhotic women. We evaluated the efficacy and safety of endometrial ablation (NovaSure therapy) for AUB in cirrhotic women. Methods This prospective, two‐arm, observational study enrolled patients for NovaSure treatment, and they were followed for 12 months. Primary measurements were the amenorrhea rate and changes of pictorial blood loss assessment chart (PBLAC) scores at 1‐month post‐therapy. Key secondary end‐points included the longevity of amenorrhea at 12 months, safety profile, and progression of cirrhosis. Results Among 88 women, 26 were cirrhotic and 62 were non‐cirrhotic. At 1‐month post‐NovaSure treatment, a significant reduction of mean PBLAC scores was observed in cirrhotic patients compared to those at baseline (0.4 ± 1.3 vs 215.2 ± 410.9, P